F m Investments LLC Raises Position in AbbVie Inc. $ABBV

F m Investments LLC boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 12.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,624 shares of the company’s stock after buying an additional 7,226 shares during the period. F m Investments LLC’s holdings in AbbVie were worth $12,367,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in ABBV. Norges Bank acquired a new stake in AbbVie in the 2nd quarter worth approximately $4,288,200,000. Nuveen LLC purchased a new position in shares of AbbVie in the first quarter worth $1,819,154,000. Laurel Wealth Advisors LLC lifted its stake in shares of AbbVie by 18,384.4% during the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after buying an additional 5,675,095 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of AbbVie by 550.9% during the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after buying an additional 3,666,521 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of AbbVie by 31.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company’s stock valued at $3,068,820,000 after acquiring an additional 3,519,187 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Down 1.8%

Shares of ABBV opened at $227.57 on Friday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The stock has a market capitalization of $402.20 billion, a PE ratio of 108.37, a P/E/G ratio of 1.42 and a beta of 0.50. The company’s 50-day simple moving average is $227.62 and its 200-day simple moving average is $206.42.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.AbbVie’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is currently 524.24%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ABBV. Daiwa America upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 7th. Bank of America lifted their price target on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Evercore ISI increased their price objective on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a report on Monday, September 22nd. Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the stock from $170.00 to $270.00 in a research note on Wednesday, September 17th. Finally, Morgan Stanley increased their price objective on shares of AbbVie from $250.00 to $255.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $241.85.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.